
José Ignacio Nolazco, MD, MMSc
@nolazco_ji
👨🏽⚕️ SUO Urologic Oncology Fellow | @harvardmed 🏥 @BWHUrology @MGHUrology @DanaFarber 🌐 #Fulbright Scholar 👨🏽🎓 MMSCI Alumni @Harvard #UroSoMe 🇦🇷🇺🇲
ID: 443377554
https://www.instagram.com/dr.joseignacionolazco/ 22-12-2011 03:46:54
1,1K Tweet
2,2K Followers
1,1K Following

Thank you Quoc-Dien Trinh, MD, MBA from UPMC Urology and Sophia Kamran, MD from Mass General Cancer Center for speaking with us on the ARANOTE trial and the AUA Guidelines for salvage therapy in prostate cancer! What great insights ✨ #AUA25


Today we officially launched Asurys™ at AUA 2025 in Las Vegas with Jose Antonio Salvadó! Proud to be part of the team that performed the first cases worldwide starting in Chile 🇨🇱. Thank you to everyone who believed, supported, and made this moment possible. #AUA2025 #Asurys

This Wednesday, PCF’s Chief Medical Officer, Phillip Koo, MD, will host a webinar to discuss rising PSA levels, what they mean and what treatment options may be available. RSVP: bit.ly/4lO00RG #MedX #MedEd


Great presentation on Augmented Reality in Urology by Daniele Amparore at the EUS with an All-star cast of moderators Dr. J. Kaouk Riccardo Autorino MD PhD FACS Dr. Giovanni E Cacciamani MD MSc FEBU 🇮🇹🇺🇸🇪🇺 Dr. Weaver Endourological Society #AUA2025 #aua25 Cleveland Clinic Urology


Avoid tumor fragmentation and seeding in bladder cancer! Jeremy Teoh #AUA25 Amer. Urol. Assn. ✅ 5mm margin marking and gentle retrograde dissection ✅ Loop rotation technique to preserve integrity ✅ Modified EBRT even for large tumors (>3cm) En bloc TURBT reduces recurrence!


#AUA25 | Joshua Meeks presented the first DFS analysis (RC population) from the NIAGARA trial evaluating perioperative durvalumab + NAC in MIBC: 📢 NIAGARA showed significant improvement in EFS (HR 0.68; 95% CI, 0.56–0.82) and OS (HR 0.75; 95% CI, 0.59–0.93) 📌 In the RC cohort: —


#AUA25 Petros Grivas presented conditional survival data from JAVELIN Bladder 100 in pts on ≥1 or ≥2 yrs of avelumab maintenance: 💊 Total: n=350 | ≥1 yr: n=118 | ≥2 yrs: n=68 📈 Survival beyond treatment: → ≥1 yr: 93% → ≥2 yrs: 96% 📊 PFS for an additional year: 67% in


#AUA25 Dr. Katharina Oberneder Sigmund Freud PrivatUniversität Wien presented data on oncologic outcomes in patients undergoing RC for NMIBC following BCG therapy failure: UroToday.com Amer. Urol. Assn.


SUO Fellowships prepare the clinicians and surgeons of the future by equipping them with a deep understanding of the pathology of urologic cancers and the expertise to treat and operate on patients. MGH Urology @BGWUrology Harvard Urology

#HoLEP Real Life “Unedited video” - 60gr - En block & Early apical release thecnique - 2J/50H Quanta Surgery Láser - 24 fr scope - 15min Enucleation - Beautiful Hemostasis & bladder neck dissection #CompartiEndourologia & #HoLEP en #LATAM #UroSome #AEEP #Prostate #Urology





Confederación Americana de Urología (CAU) siupurol Importante conocer la realidad en LATAM del cancer de vejiga en cuanto a adherencia a guías clínicas Gustavo Villoldo Luis Ebel Alejandro Rodriguez, MD, FACS Hegel T-Santamaría José Ignacio Nolazco, MD, MMSc Sociedad Chilena de Urología Rafael Sanchez-Salas Óscar Rodríguez Faba Joan Palou Redorta Rodrigo Ledezma Marcelo Baptistussi Nahuel Paesano Georgina Gentili Francisco López


Tobacco Users Have Higher Risk of Complications and Death After Partial Nephrectomy brighamhealthonamission.org/2025/05/21/tob… MassGeneral News Harvard Health Urologic Oncology #PartialNephrectomies #RenalCancer

Building future #Oncology leaders beyond clinical training. José Ignacio Nolazco, MD, MMSc Brigham and Women's Hospital Department of Urology joins Zach Klaassen Georgia Cancer Center to discuss his experience attending the #GUOncology Early Thought Leaders Conference. Dr. Nolazco shares how the conference uniquely focused on "soft skills"

